Evercore ISI started coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research note published on Monday, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $25.00 price target on the stock.
MIRM opened at $13.45 on Monday. Mirum Pharmaceuticals has a fifty-two week low of $12.05 and a fifty-two week high of $15.50.
In other news, major shareholder Holdings A/S Novo acquired 575,000 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was bought at an average price of $15.00 per share, with a total value of $8,625,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider James E. Flynn acquired 332,000 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was purchased at an average cost of $15.00 per share, with a total value of $4,980,000.00. The disclosure for this purchase can be found here. Insiders acquired 1,357,000 shares of company stock valued at $20,355,000 in the last ninety days.
Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Recommended Story: Convertible Shares
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.